

Roman Chicz, PhD, Global Project
Head, Recombinant COVID Vaccine

56



SANOFI PASTEUR 

BIO Panel: Covid-19 Vaccine
Development Update







November 2021

57



60


We continue to support the global supply of primary vaccines
Leveraging our expertise and capacity to manufacture COVID-19 vaccines

		
 <p>125 million doses Frankfurt Site</p>	 <p>12 million doses per month Marcy l'Etoile Site</p>	 <p>Up to 200 million doses Ridgefield Site</p>
<p>About 500 million doses of primary vaccines will be produced by SP for the other manufacturers</p>		
		

61

Fluzone High-Dose® vaccine and Moderna mRNA-1273 vaccine Co-administration Study Design

- Descriptive study with ~300 participants (100 per group)
- Randomized, open label, conducted in the US
- Participants received 2 doses of mRNA-1273 vaccine at least 5 months before enrollment
- mRNA-1273 vaccine booster dose (100µg)
- QIV-HD 2021-2022 formulation (240µg)
- Offered to Group 3 participants at D22 as part of routine medical care



SANOPI PASTEUR

| 6

62

Co-administration Findings Support the Recent ACIP Recommendation

The QHD00028 study results demonstrate that QIV-HD and mRNA-1273 vaccine (100µg) can be administered safely together without evidence of immunogenicity interference, supporting existing co-administration recommendations of COVID-19 and influenza vaccines.

SANOPI PASTEUR

| 7

63

